The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of autoimmune disease on toxicity and outcomes after idecabtagene vicleucel in patients with multiple myeloma.
 
Rebecca Albuquerque
No Relationships to Disclose
 
Anna Shamis
No Relationships to Disclose
 
Athanasios Tsalatsanis
No Relationships to Disclose
 
Melissa Alsina
Consulting or Advisory Role - BMS; Janssen Oncology; Sanofi
Research Funding - BMS; Janssen Biotech; Pfizer
 
Hien Liu
Honoraria - BioLineRx
Consulting or Advisory Role - BioLineRx
 
Doris Hansen
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bristol Myers Squibb Foundation; Janssen; Karyopharm Therapeutics; Kite/Gilead; Legend Biotech; Pfizer
Research Funding - Adaptive Biotechnologies; Bristol-Myers Squibb/Celgene; Janssen; Karyopharm Therapeutics; Kite, a Gilead company
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene; Janssen
 
Nancy Torres
No Relationships to Disclose
 
Rawan Faramand
Consulting or Advisory Role - Autolus; Gilead Sciences; Sanofi
Research Funding - Kite, a Gilead company (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Sanofi
 
Ciara Freeman
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; ONK Therapeutics
Research Funding - Bristol-Myers Squibb/Celgene
 
Julio Chavez
No Relationships to Disclose
 
Fabiana Perna
Consulting or Advisory Role - Orbital therapeutics
Research Funding - Lonza
Patents, Royalties, Other Intellectual Property - Adoptive cellular therapy
 
Michael Jain
Consulting or Advisory Role - Kite/Gilead; Novartis
Research Funding - Incyte (Inst); Kite/Gilead (Inst); Loxo/Lilly (Inst)
Travel, Accommodations, Expenses - Kite/Gilead
 
Taiga Nishihori
Consulting or Advisory Role - Immunogen
Research Funding - Karyopharm Therapeutics (Inst); Novartis (Inst)
 
Brandon Blue
Honoraria - Abbvie; Janssen Oncology; Kite, a Gilead company; Oncopeptides; Pfizer; Takeda
Consulting or Advisory Role - Janssen
Speakers' Bureau - Sanofi
 
Rachid Baz
No Relationships to Disclose
 
Omar Castañeda Puglianini
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene/Juno; Legend Biotech
Speakers' Bureau - Bristol Myers Squibb
 
Ariel Grajales-Cruz
No Relationships to Disclose
 
Kenneth Shain
No Relationships to Disclose
 
Frederick Locke
Consulting or Advisory Role - A2 Biotherapeutics; Alimera Sciences; Amgen; Bluebird Bio; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Calibr; Caribou Biosciences; Celgene; Cowen; Daiichi Sankyo/UCB Japan; EcoR1 Capital; Gerson Lehrman Group; Iovance Biotherapeutics; Janssen; Kite, a Gilead company; Legend Biotech; Miltenyi Biotec; Novartis; Sana Biotechnology; Takeda; Takeda; Umoja Biopharma
Research Funding - Alimera Sciences (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb/Celgene (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics; Kite, a Gilead company
 
Abu-Sayeef Mirza
No Relationships to Disclose